Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $27.84 USD
Change Today +0.39 / 1.42%
Volume 454.7K
RTRX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

retrophin inc (RTRX) Snapshot

Open
$27.21
Previous Close
$27.45
Day High
$28.31
Day Low
$27.21
52 Week High
08/5/15 - $37.04
52 Week Low
10/1/14 - $7.85
Market Cap
995.2M
Average Volume 10 Days
718.7K
EPS TTM
$-3.69
Shares Outstanding
35.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RETROPHIN INC (RTRX)

retrophin inc (RTRX) Details

Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious, catastrophic, or rare diseases. Its product line includes Cholbam, a cholic acid for the treatment of bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of peroxisomal disorders, such as Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea, or complications from decreased fat soluble vitamin absorption; Thiola, which is indicated for the prevention of cystine stone formation in patients with severe homozygous cystinuria with urinary cystine greater than 500 mg/day, who are resistant to treatment with conservative measures of high fluid intake, alkali and diet modification, or who have adverse reactions to d-penicillamine; and Chenodal, a synthetic oral form of chenodeoxycholic acid for radiolucent stones in well-opacifying gallbladders. The company’s product pipeline also includes compounds for various catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome, and others. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.

127 Employees
Last Reported Date: 08/10/15
Founded in 2011

retrophin inc (RTRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $323.2K
Executive Vice President of Research and Deve...
Total Annual Compensation: $430.8K
General Counsel and Secretary
Total Annual Compensation: $95.8K
Compensation as of Fiscal Year 2014.

retrophin inc (RTRX) Key Developments

Retrophin, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Sales Guidance for the Full Year 2015

Retrophin, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the second quarter 2015, the company reported that it recorded a GAAP net loss of USD 25.5 million or USD 0.73 per basic share. This marks a decline when compared to net income of USD 11.8 million or USD 0.77 per diluted share for the corresponding period in 2014. Net product sales of USD 24.1 million were recorded for the second quarter of 2015, up over net product sales of USD 5.7 million for the second quarter of 2014. The company said the increase in net product sales is due to the acquisition and subsequent commercial launch of two additional orphan disease products, Thiola and Cholbam. Operating loss was $6.824 million against $17.182 million a year ago. Loss before income taxes was $25.51 million against income of $9.28 million a year ago. Non-GAAP operating income was $3.21 million against loss of $11.53 million a year ago. Non-GAAP net income was $13.94 million against loss of $13.34 million a year ago. Non-GAAP basic earnings per share were $0.40 against loss of $0.52 a year ago. For the six months, the company reported net product sales was $41.4 million against $5.77 million a year ago. Operating loss was $14.93 million against $39.24 million a year ago. Loss before income taxes was $25.88 million against $66.39 million a year ago. Net income was $14.13 million or $0.44 diluted per share against loss of $63.93 million or $2.61 diluted per share a year ago. Non-GAAP operating income was $4.57 million against loss of $29.07 million a year ago. Non-GAAP net income was $12.38 million against loss of $30.87 million a year ago. Non-GAAP basic earnings per share were $0.40 against loss of $1.26 a year ago. The company expects full year 2015 net product sales to be in the range of $95 to $100 million.

Retrophin, Inc. to Report Q2, 2015 Results on Aug 04, 2015

Retrophin, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Aug 04, 2015

Retrophin, Inc., Q2 2015 Earnings Call, Aug 04, 2015

Retrophin, Inc., Q2 2015 Earnings Call, Aug 04, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RTRX:US $27.84 USD +0.39

RTRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioMarin Pharmaceutical Inc $133.18 USD +2.29
GlaxoSmithKline PLC 1,341 GBp +9.50
Pfizer Inc $32.66 USD -0.60
Shire PLC 5,025 GBp +10.00
View Industry Companies
 

Industry Analysis

RTRX

Industry Average

Valuation RTRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.2x
Price/Book 6.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RETROPHIN INC, please visit www.retrophin.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.